TABLE 2.

Clinical trials with cediranib in ovarian cancer.

Name of the study	Year of the study	Phase of the study	Research group	Dose of cediranib	Results
ICON6 (Ledermann et al., 2021)	2021	III	456, (chemotherapy plus placebo n = 118, chemotherapy plus cediranib with placebo maintenance n = 174, chemotherapy plus cediranib with cediranib maintenance n = 164)	Daily dose 20 mg	Chemotherapy plus placebo, chemotherapy plus cediranib with placebo maintenance, chemotherapy plus cediranib with cediranib maintenance: OS 19.9, 26.6, 27.3 months, respectively
NRG-GY004 (Liu et al., 2019)	2022	III	565, (platinum-based chemotherapy n = 187, olaparib alone n = 189, olaparib plus cediranib)	30 mg once daily	Platinum-based chemotherapy, olaparib alone, olaparib plus cediranib: PFS 10.3, 8.2, 10.4 months; OS 31.2, 29.2, 31.3, respectively

PFS, progression-free survival; OS, overall survival.